March 4, 2024
A clinical trial led by University of Cincinnati researchers at the Lindner Center of HOPE found the drug liraglutide was safe and effective for weight loss for patients with stable bipolar disorder.
December 20, 2023
The University of Cincinnati's Francisco Romo-Nava published research in the journal Molecular Psychiatry that found noninvasive spinal cord stimulation is safe and has therapeutic potential to treat depression.
December 21, 2023
U.S. News & World Report highlighted research led by the University of Cincinnati's Francisco Romo-Nava that found spinal cord stimulation was well tolerated and has therapeutic potential to treat depression.
January 9, 2024
A new trial at the University of Cincinnati Gardner Neuroscience Institute, funded by a $660,000 National Institutes of Health (NIH) grant, will test an at-home tongue endurance exercise to improve patients’ swallowing function after a stroke.
January 11, 2024
WVXU highlighted a new trial at the University of Cincinnati that will test an at-home tongue endurance exercise to improve patients’ swallowing function after a stroke.
January 29, 2024
Researchers are passionate about their fields of study for a variety of reasons. For Satish Madala, his focus on asthma is deeply personal. “This is my ‘close to heart’ project because I came to this research area mainly because of my childhood asthma,” says Madala, PhD, of the UC College of Medicine.
March 18, 2024
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing symptoms for longer periods of time.
March 26, 2024
A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, the most deadly form of brain tumors.
March 6, 2024
University of Cincinnati Cancer Center researchers in the lab of Jun-Lin Guan, PhD, have identified a new protein that helps prevent metastasis of a subset called HER2-positive breast cancer.
April 4, 2024
Clinical research conducted at the University of Cincinnati College of Medicine and UC Health played a role in the U.S. Food and Drug Administration's March 26 approval of WINREVAIR™ (sotatercept-csrk) for the treatment of pulmonary arterial hypertension (PAH) in adults.